
AVITA Medical rose 304.9% from $3.86 to $15.63, ahead of the S&P 500's +13.3%. Its worst day was Mar 3 (−8.7%), and its low came Dec 17 at $3.27.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
AVITA Medical closed at its lowest level of the year, 15.3% below where the year started.
−1.8% · S&P 500 −1.1%
EPS of $-0.38 beat the $-0.47 estimate on $17.6M revenue (est. $25.2M); FY revenue guidance of $80.0M–$85.0M against the $123.5M consensus.
Story events cover the past 12 months · Times ET
+11.8% · S&P 500 +0.1%
EPS of $-0.35 beat the $-0.38 estimate on $19.3M revenue (est. $24.3M); FY revenue guidance of $80.0M–$85.0M against the $109.8M consensus.
+4.6% · S&P 500 −1.2%
AVITA Medical shares rose 17.7%, while the S&P 500 rose 0.4%.
+17.7% · S&P 500 +0.4%
EPS of $-0.25 beat the $-0.37 estimate on $21.7M revenue (est. $28.6M); FY revenue guidance of $86.0M–$89.0M against the $117.6M consensus.
+63.6%, the year's best day, on 7M shares, the year's heaviest volume · S&P 500 +0.6%
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical
+24.7% · S&P 500 −0.7%
EPS of $-0.20 beat the $-0.29 estimate on $25.9M revenue (est. $32.1M); Q4 revenue guidance of $24.9M–$26.9M against the $34.7M consensus.
+5.8% · S&P 500 +0.3%
Where it ended: a close of $15.63 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-0.14, revenue est. $37.5M).
Nothing in the past 12 months.
All RCEL dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RCEL and SPY from Benzinga historical bars. Not investment advice.